Medlab to be granted European patent for NanoCelle® drug delivery platform
DATE: Wednesday 7th April 2021
Medlab Clinical is pleased to announce it has received an Intention to Grant notice from the European Patent Office for its patent covering the use of the Company’s NanoCelle® sub-micron delivery platform in Europe, including the UK.
The patent, filed in 2016 and titled Transmucosal and transdermal delivery systems, will provide protection for NanoCelle® in European member states as well as the United Kingdom until 2036.
This is the second patent granted for NanoCelle®, following the receipt of an Australian patent in September 2020. Medlab has also filed patent applications in the US, Canada, New Zealand, Singapore and Hong Kong.
Read more about our market release available at SmallCaps.
NanoCelle® is Medlab’s proprietary sub-micron delivery system. NanoCelle® creates nano-sized water-soluble particles that enable optimised delivery of particles, overcoming issues with solubility and degradation. NanoCelle® has potential applications in and out of medicine, including small and large molecule pharmaceuticals, generic medicines, cosmetics, nutraceuticals, and textiles. NanoCelle® underpins Medlab’s growth strategy by offering near-term partnering opportunities whilst enhancing the Company’s pharmaceutical and nutraceutical portfolios.
About the author
Medlab in-house Editor.